The scheme, which launched in 2014, helps to give patients with life threatening or seriously debilitating conditions earlier access to new and innovative treatments.
Medicines developers, including research organisations, can apply for a PIM designation if they have evidence to support that a medicinal product is likely to offer major advantage for patients. Upon designation, the application can then proceed to a scientific opinion assessment which leads to patient access in the NHS.
EAMS is a key part of our commitment to accelerating patient access to innovative treatments and supporting the UK life sciences environment. Between April 2014 and December 2017, 18 positive scientific opinions have been awarded in a number of different clinical areas with unmet medical need.
Dr Ian Hudson, Chief Executive Officer at MHRA said:
Reaching this milestone means 50 new indications from promising medicinal products have emerged in the last four years alone. As a result, current and future patients will be able to access potentially life-saving drugs that they may not have otherwise had the chance to have.
We are delighted with the success of the scheme, to date, which is part of our priority to ensure, new, good quality, safe and efficacious innovative treatments are available to patients at the earliest opportunity.